Navigation Links
Questcor to Report First Quarter Results on April 30, 2013
Date:4/15/2013

ANAHEIM, Calif., April 15, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced that it will release first quarter 2013 financial results on Tuesday, April 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, April 30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 34200996.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Fourth Quarter and Full Year 2012 Results
2. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
3. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
4. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
6. Questcor to Conduct Conference Call to Discuss Reimbursement Process
7. Questcor Comments on Insurance Policy Bulletin
8. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
9. Questcor Pharmaceuticals to Present at Investor Conferences in September
10. Questcor Reports Second Quarter Financial Results
11. Questcor to Report Second Quarter Results on July 24, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... Carnival Vista – the line’s largest cruise ship ever. To help guests ... an infographic spotlighting the Carnival Vista ’s most exciting features and ...
(Date:5/2/2016)... ... May 02, 2016 , ... Those ... rehabilitation center can find some useful information in a new video released by ... This video, which can be viewed on the Serenity Recovery YouTube channel, examines ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pets bring laughter, joy and love ... pet owners celebrate National Pet Week, which falls on the first full week of ... to cherish the human-animal bond and recognize responsible pet ownership. Pet owners can live ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance ... understand life insurance throughout various life stages. , The site launched on April ... calculator and content specific to the times when life insurance matters most. , ...
(Date:5/2/2016)... ... 02, 2016 , ... WestHarbor Growth Partners, a growth, expansion ... of Grow Healthy Vending’s newly revamped brand campaign. Grow Healthy Vending is ... providers in North America with locations across the United States as well as ...
Breaking Medicine News(10 mins):